昂拉地韦

昂拉地韦
臨床資料
商品名（英语：Drug nomenclature）	安睿威
给药途径	口服
法律規範狀態
法律規範	中：处方药 ;
识别信息
	IUPAC命名法 (2S,3S)-3-(6 - 环丙基 - 5 - 氟 - 2-(5 - 氟 - 1H - 吡唑醇 (3,4-b) 吡啶 - 3 - 基) 吡啶 - 4 - 基) 氨基) 双环 (2.2.2) 辛烷 - 2 - 羧酸; ;
CAS号	2200336-20-3
PubChem CID	138746841;
化学信息
化学式	C22H22F2N6O2
摩尔质量	440.4
3D模型（JSmol（英语：JSmol））	交互式图像;
	SMILES C1CC2CCC1[C@@H]([C@H]2NC3=NC(=NC(=C3F)C4CC4)C5=C6C=C(C=NC6=NN5)F)C(=O)O;
	InChI InChI=1S/C22H22F2N6O2/c23-12-7-13-18(29-30-19(13)25-8-12)21-27-17(11-5-6-11)15(24)20(28-21)26-16-10-3-1-9(2-4-10)14(16)22(31)32/h7-11,14,16H,1-6H2,(H,31,32)(H,25,29,30)(H,26,27,28)/t9?,10?,14-,16-/m0/s1; Key:JCHDJLSIYWBAHI-ZWHBIUKWSA-N;

昂拉地韦（英語：Onradivir），商品名安睿威，开发代号ZSP1273，^[1]是一种被中国国家药品监督管理局批准用于治疗成人单纯性甲型流感患者的治疗的抗病毒药物。^[2]本品由广东众生睿创生物科技有限公司开发，药物靶点为甲型流感病毒复制过程中的RNA聚合酶PB2亚基。在体外研究中，即使对巴洛沙韦与奥司他韦耐药的甲型流感毒株仍对ZSP1273敏感；然而，本品在体外无法有效抑制乙型流感病毒。^[1]

在II期临床中，与安慰剂相比，600mg每日昂拉地韦可将成人甲流患者的缓解流感症状的中位时间缩短22.82小时，最常报告的治疗中出现的不良事件是腹泻。^[3]

参考资料

^ ^1.0 ^1.1 Chen, X; Ma, Q; Zhao, M; Yao, Y; Zhang, Q; Liu, M; Yang, Z; Deng, W. Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase.. Pharmaceuticals (Basel, Switzerland). 2023-02-27, 16 (3). PMC 10056986 . PMID 36986465. doi:10.3390/ph16030365.
^ 国家药监局批准昂拉地韦片上市. 国家药品监督管理局. 2025-05-22 （中文（简体））.
^ Yang, Zifeng; Li, Zhengtu; Zhan, Yangqing; Lin, Zhengshi; Fang, Zhonghao; Xu, Xiaowei; Lin, Lin; Li, Haijun; Lin, Zejun; Kang, Changyuan; Liang, Jingyi; Liang, Shiwei; Li, Yongming; Li, Shaoqiang; Yang, Xinyun; Ye, Feng; Zhong, Nanshan; Zhang, Ping; Li, Xiaoguang; Peng, Jie; Li, Sanjing; Jiang, Rongmeng; Chen, Xiaolin; Fu, Yingyun; Zeng, Huiqing; Zhang, Xiaoju; Zhang, Wei; Yu, Shenghui; Gao, Feng; Lin, Changqing; Mu, Deguang; Chai, Yanfen; Chen, Mei; Zheng, Xianyong. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2024-05, 24 (5): 535–545. PMID 38330975. doi:10.1016/S1473-3099(23)00743-0.

[invitro-1] 1.0 ^1.1 Chen, X; Ma, Q; Zhao, M; Yao, Y; Zhang, Q; Liu, M; Yang, Z; Deng, W. Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase.. Pharmaceuticals (Basel, Switzerland). 2023-02-27, 16 (3). PMC 10056986 . PMID 36986465. doi:10.3390/ph16030365.

[2] 国家药监局批准昂拉地韦片上市. 国家药品监督管理局. 2025-05-22 （中文（简体））.

[3] Yang, Zifeng; Li, Zhengtu; Zhan, Yangqing; Lin, Zhengshi; Fang, Zhonghao; Xu, Xiaowei; Lin, Lin; Li, Haijun; Lin, Zejun; Kang, Changyuan; Liang, Jingyi; Liang, Shiwei; Li, Yongming; Li, Shaoqiang; Yang, Xinyun; Ye, Feng; Zhong, Nanshan; Zhang, Ping; Li, Xiaoguang; Peng, Jie; Li, Sanjing; Jiang, Rongmeng; Chen, Xiaolin; Fu, Yingyun; Zeng, Huiqing; Zhang, Xiaoju; Zhang, Wei; Yu, Shenghui; Gao, Feng; Lin, Changqing; Mu, Deguang; Chai, Yanfen; Chen, Mei; Zheng, Xianyong. Safety and efficacy of onradivir in adults with acute uncomplicated influenza A infection: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2024-05, 24 (5): 535–545. PMID 38330975. doi:10.1016/S1473-3099(23)00743-0.

[1]

[2]

[3]